Bullish sentiment from experts for Krystal Biotech with positive revenue growth and strong financials

From Nasdaq: 2025-05-16 18:00:00

In the past three months, 12 analysts have provided varied perspectives on Krystal Biotech (NASDAQ: KRYS), with ratings ranging from bullish to bearish. Recent data shows a total of 9 bullish, 1 somewhat bullish, and 2 indifferent ratings. The average price target for Krystal Biotech is $218.17, with a high estimate of $245.00 and a low estimate of $155.00. Analysts have made adjustments to their ratings and price targets, reflecting changing market conditions and company performance. Krystal Biotech specializes in developing gene therapies for rare dermatological diseases, showcasing positive revenue growth and strong financial indicators.



Read more at Nasdaq: The Analyst Verdict: Krystal Biotech In The Eyes Of 12 Experts